Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-A y/Ta mice

Nephron - Experimental Nephrology

Volumn 117, Issue 4, 2011, Pages

  Ohara, Ikko ^a   Tanimoto, Mitsuo ^a   Gohda, Tomohito ^a   Yamazaki, Takahiko ^a   Hagiwara, Shinji ^a   Murakoshi, Maki ^a   Aoki, Tatsuya ^a   Toyoda, Hitoe ^a   Ishikawa, Yuji ^a   Funabiki, Kazuhiko ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 (AT1) receptor blocker; Diabetic nephropathy; Vitamin D

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CREATININE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RENIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; CALCITRIOL; CHEMOKINE CCL2; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; GENE EXPRESSION; KIDNEY; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RENIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 77957780608     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320284     Document Type: Article

References (38)

1. Brewster UC, Perazella MA: The renin-angiotensin- aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116: 263-272. (Pubitemid 38224234)
2. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619. (Pubitemid 15227525)
3. Luft FC: Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2002; 11: 59-66.
4. Wolf G: Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000; 15: 61-63.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
7. Muller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221-228.
8. 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
9. 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52.
10. Kaneshiro Y, Ichihara A, Sakoda M, et al: Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795. (Pubitemid 46870315)
11. Kuhlman A, Haas CS, Gross ML, et al: 1,25-Dihydroxyvitamin D 3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286:F526-F533. (Pubitemid 38233647)
12. Makibayashi K, Tatematsu M, Hirata M, et al: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001; 158: 1733-1741. (Pubitemid 32422938)
13. Panichi V, Migliori M, Taccola D, et al: Effects of 1,25(OH) 2 D 3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60: 87-95.
14. Schwarz U, Amman K, Orth SR, et al: Effects of 1,25(OH) 2 vitamin D 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696-1705.
15. Li YC, Kong J, Wei M, et al: Vitamin D: A negative endocrine regulator of the renin angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90: 387-392. (Pubitemid 38844316)
16. 3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
17. Zhang Z, Zhang Y, Ning G, et al: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 41: 15896-15901.
18. Fan Q, Liao J, Kobayashi M, et al: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020. (Pubitemid 40057622)
19. y/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006; 11: 29-35.
20. Manucha W, Carrizo L, Ruete C, et al: Angiotensin II type 1 antagonist on oxidative stress and heat-shock protein 70 (HSP70) expression in obstructive nephropathy. Cell Mol Biol (Noisy-le grand) 2005; 51: 547-555. (Pubitemid 41696412)
21. Fryer RM, Rakestraw PA, Nakane M, et al: Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/ BL6 mice. Nephron Physiol 2007; 106: 76-81.
22. y mice. Exp Anim 2002; 51: 191-196.
23. El-Nahas AM, et al: Role of growth hormone in the development of experimental renal scarring. Kidney Int 1991; 40: 29-34.
24. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317: 703-713.
25. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-1637.
26. 3 and rat vascular smooth muscle cell growth. Hypertension 1989; 13: 954-959.
27. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy Lancet 1998; 352: 213-219.
28. Perkins BA, Ficociello LH, Ostrander BE, et al: Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18: 1353-1361. (Pubitemid 46536923)
29. Eijkelkamp WB, Zhang Z, Remuzzi G, et al: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post-hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546. (Pubitemid 46717521)
30. Nguyan G, Delarue F, Burcklé C, et al: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427. (Pubitemid 34596167)
31. Cardús A, Panizo S, Parisi L, et al: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866. (Pubitemid 351339746)
32. Price PA, June HH, Bucley JR, et al: Osteo-protegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616. (Pubitemid 34215580)
33. Li Y, Spataro BC, Yang J, et al: 1,25-Dihydroxyvitamin D 3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-1510.
34. Mizobuchi M, Morrissey J, Finch JL, et al: Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806. (Pubitemid 46870316)
35. Hullet DA, Laeseke PF, Malin G: Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005; 18: 1175-1186. (Pubitemid 41726762)
36. Parving HH, Persson F, Lewis JB, et al for the AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
37. Atsuhisa S, Hayashi K, Mitsuhide N, Takao S: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68. (Pubitemid 36056793)
38. Hiroyuki O, Fumio O, Kenichi I, et al: Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008; 149: 2816-2825.